Latest News and Press Releases

June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”),...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful...

June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone...

EarlyHealth Group Acquires Corena to Drive $100M Growth in Türkiye’s Life Sciences Sector

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

TEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company developing therapies for aneurysmal disease, announced today that the American Medical...

EXTON, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the...

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute...

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first...